5,819 Shares in Corteva, Inc. $CTVA Bought by Corton Capital Inc.

Corton Capital Inc. purchased a new stake in shares of Corteva, Inc. (NYSE:CTVA) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 5,819 shares of the company’s stock, valued at approximately $434,000. Corteva accounts for approximately 0.5% of Corton Capital Inc.’s investment portfolio, making the stock its 24th largest position.

Other hedge funds have also bought and sold shares of the company. Peak Financial Advisors LLC bought a new position in Corteva in the second quarter worth approximately $505,000. Cary Street Partners Financial LLC lifted its holdings in shares of Corteva by 20.7% during the 1st quarter. Cary Street Partners Financial LLC now owns 90,206 shares of the company’s stock valued at $5,677,000 after purchasing an additional 15,448 shares during the last quarter. PGGM Investments lifted its holdings in shares of Corteva by 68.5% during the 2nd quarter. PGGM Investments now owns 1,223,444 shares of the company’s stock valued at $91,183,000 after purchasing an additional 497,200 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Corteva by 28.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,851,993 shares of the company’s stock worth $179,476,000 after acquiring an additional 634,938 shares during the last quarter. Finally, S.E.E.D. Planning Group LLC raised its stake in Corteva by 70.3% in the 2nd quarter. S.E.E.D. Planning Group LLC now owns 164,393 shares of the company’s stock worth $12,252,000 after acquiring an additional 67,869 shares during the last quarter. Institutional investors own 81.54% of the company’s stock.

Corteva Stock Down 0.3%

Shares of NYSE CTVA opened at $61.51 on Monday. Corteva, Inc. has a 12-month low of $53.40 and a 12-month high of $77.41. The stock has a market cap of $41.77 billion, a P/E ratio of 30.00, a PEG ratio of 1.40 and a beta of 0.76. The company has a current ratio of 1.68, a quick ratio of 1.23 and a debt-to-equity ratio of 0.06. The business’s fifty day simple moving average is $67.53 and its 200-day simple moving average is $69.40.

Corteva (NYSE:CTVA) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $2.20 earnings per share for the quarter, topping the consensus estimate of $1.89 by $0.31. Corteva had a return on equity of 8.68% and a net margin of 8.16%.The company had revenue of $6.46 billion for the quarter, compared to the consensus estimate of $6.26 billion. During the same quarter in the prior year, the business earned $1.83 EPS. Corteva’s revenue was up 5.6% on a year-over-year basis. As a group, equities analysts predict that Corteva, Inc. will post 2.96 EPS for the current fiscal year.

Corteva Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 15th. Stockholders of record on Monday, December 1st will be given a dividend of $0.18 per share. This represents a $0.72 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, December 1st. Corteva’s dividend payout ratio (DPR) is 35.12%.

Insider Buying and Selling at Corteva

In other news, EVP Robert D. King sold 37,280 shares of the firm’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $74.20, for a total transaction of $2,766,176.00. Following the sale, the executive vice president owned 49,262 shares of the company’s stock, valued at approximately $3,655,240.40. This trade represents a 43.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on CTVA shares. Citigroup lowered Corteva from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $83.00 to $70.00 in a report on Thursday, October 2nd. Oppenheimer lowered their price objective on Corteva from $87.00 to $75.00 and set an “outperform” rating on the stock in a report on Wednesday, October 22nd. Royal Bank Of Canada lowered their price objective on Corteva from $86.00 to $80.00 and set an “outperform” rating on the stock in a report on Friday, October 17th. Argus lowered their target price on Corteva from $83.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, October 13th. Finally, Wolfe Research reduced their price target on shares of Corteva from $80.00 to $79.00 and set an “outperform” rating on the stock in a research report on Monday, October 27th. Fifteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $79.65.

Corteva Company Profile

Corteva, Inc operates in the agriculture business. It operates through two segments, Seed and Crop Protection. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms. It offers trait technologies that enhance resistance to weather, disease, insects, and herbicides used to control weeds, as well as food and nutritional characteristics.